150 related articles for article (PubMed ID: 29629566)
1. Why does chemotherapy stop affecting the cells of ovarian and breast tumors?
Kalinina EV; Chernov NN
Future Oncol; 2018 May; 14(12):1137-1140. PubMed ID: 29629566
[No Abstract] [Full Text] [Related]
2. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of chemotherapy resistance in ovarian cancer.
Cooley M; Fang P; Fang F; Nephew KP; Chien J
Pharmacogenomics; 2015 Nov; 16(16):1763-7. PubMed ID: 26554863
[No Abstract] [Full Text] [Related]
4. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance in breast cancer--is the jury in yet?
Kaye SB
J Natl Cancer Inst; 1997 Jul; 89(13):902-3. PubMed ID: 9214663
[No Abstract] [Full Text] [Related]
6. Characteristics of homocysteine-induced multidrug resistance of human MCF-7 breast cancer cells and human A2780 ovarian cancer cells.
Lukyanova NY
Exp Oncol; 2010 Mar; 32(1):10-4. PubMed ID: 20332764
[TBL] [Abstract][Full Text] [Related]
7. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation.
Kalinina EV; Berezov TT; Shtil' AA; Chernov NN; Glazunova VA; Novichkova MD; Nurmuradov NK
Bull Exp Biol Med; 2012 Oct; 153(6):878-81. PubMed ID: 23113308
[TBL] [Abstract][Full Text] [Related]
8. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells.
Huang MJ; Zhang W; Wang Q; Yang ZJ; Liao SB; Li L
J Ovarian Res; 2018 Feb; 11(1):15. PubMed ID: 29433550
[TBL] [Abstract][Full Text] [Related]
9. Expression of genes for thioredoxin 1 and thioredoxin 2 in multidrug resistance ovarian carcinoma cells SKVLB.
Kalinina EV; Chernov NN; Saprin AN; Kotova YN; Gavrilova YA; Chermnykh NS; Shcherbak NP
Bull Exp Biol Med; 2007 Sep; 144(3):301-3. PubMed ID: 18457020
[TBL] [Abstract][Full Text] [Related]
10. Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer.
He D; Li T; Sheng M; Yang B
Med Sci Monit; 2020 Mar; 26():e918751. PubMed ID: 32167078
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
16. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
Samuel P; Pink RC; Brooks SA; Carter DR
Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
[TBL] [Abstract][Full Text] [Related]
17. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
[TBL] [Abstract][Full Text] [Related]
18. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
20. Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer.
Li S; Cao J; Zhang W; Zhang F; Ni G; Luo Q; Wang M; Tao X; Xia H
Sci Rep; 2016 Nov; 6():36873. PubMed ID: 27833130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
